SCHEMBL13437313

SCHEMBL13437313

CCOC(=O)c1nc(-c2cccnc2)sc1CC(C)C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 5/20 0.56
DBF4 Q9UBU7 5/20 0.56
FBP1 P09467 1/20 0.51
KDM4E B2RXH2 6/20 0.49
ALDH1A1 P00352 4/20 0.49
LMNA P02545 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
GFER P55789 1/20 0.47
MAPT P10636 3/20 0.47
POLB P06746 3/20 0.47
MEN1 O00255 1/20 0.47
NPC1 O15118 1/20 0.47
NFKB1 P19838 1/20 0.47
RAB9A P51151 1/20 0.47
NFKB2 Q00653 1/20 0.47
KMT2A Q03164 1/20 0.47
RELA Q04206 1/20 0.47
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13437316 0.87 L3MBTL1 (0.60) CDC7DBF4FBP1KDM4EALDH1A1
SCHEMBL13437315 0.86 CDC7 (0.58) CDC7DBF4L3MBTL1TRPM8
SCHEMBL20022399 0.83 CDC7 (0.62) CDC7DBF4KDM4EALDH1A1LMNA
SCHEMBL13437330 0.83 TRPM8 (0.47) CDC7DBF4KDM4EALDH1A1LMNA
SCHEMBL13437332 0.82 TRPM8 (0.56) CDC7DBF4KDM4EALDH1A1MAPT
SCHEMBL13437328 0.81 TRPM8 (0.49) CDC7DBF4KDM4EMAPTMEN1
SCHEMBL289392 0.81 CDC7 (0.60) CDC7DBF4KDM4EALDH1A1LMNA
SCHEMBL289684 0.81 CDC7 (0.60) CDC7DBF4KDM4EALDH1A1LMNA
SCHEMBL13437321 0.81 TRPM8 (0.61) LMNAMAPTMEN1KMT2AL3MBTL1
SCHEMBL13437333 0.81 TRPM8 (0.61) CDC7DBF4KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2030974-B1 THIAZOLE NON-NUCLEOSIDE COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITION AND THEIR USE AS ANTIVIRAL AGENTS SHANGHAI INST MATERIA MEDICA (CN) 2016-02-17 EP disclosed
US-8653115-B2 Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2014-02-18 US disclosed
US-8653115-B2 Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2014-02-18 US disclosed
US-20100056569-A1 Heterocyclic Non-Nucleoside Compounds, Their Preparation, Pharmaceutical Composition And Their Use As Antiviral Agents SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2010-03-04 US disclosed
US-20100056569-A1 Heterocyclic Non-Nucleoside Compounds, Their Preparation, Pharmaceutical Composition And Their Use As Antiviral Agents SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2010-03-04 US disclosed
EP-2030974-A1 HETEROCYCLIC NON-NUCLEOSIDE COMPOUNDS, THEIR PEPARATION, PHARMACEUTICAL COMPOSITION AND THEIR USE AS ANTIVIRAL AGENTS Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2009-03-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056569-A1 Heterocyclic Non-Nucleoside Compounds, Their Preparation, Pharmaceutical Composition And Their Use As Antiviral Agents TYMP, PNP, NUDT1 CDC7 1256/4885DBF4 471/4885FBP1 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.